KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Depreciation and Depletion (2016 - 2022)

Historic Depreciation and Depletion for TherapeuticsMD (TXMD) over the last 13 years, with Q4 2022 value amounting to $200000.0.

  • TherapeuticsMD's Depreciation and Depletion rose 20000.0% to $200000.0 in Q4 2022 from the same period last year, while for Sep 2023 it was $200000.0, marking a year-over-year decrease of 3333.33%. This contributed to the annual value of $600000.0 for FY2022, which is 5000.0% up from last year.
  • Per TherapeuticsMD's latest filing, its Depreciation and Depletion stood at $200000.0 for Q4 2022, which was up 20000.0% from $200000.0 recorded in Q3 2022.
  • Over the past 5 years, TherapeuticsMD's Depreciation and Depletion peaked at $200000.0 during Q2 2020, and registered a low of -$200000.0 during Q4 2021.
  • In the last 5 years, TherapeuticsMD's Depreciation and Depletion had a median value of $187625.0 in 2019 and averaged $124020.6.
  • In the last 5 years, TherapeuticsMD's Depreciation and Depletion skyrocketed by 20049.88% in 2020 and then plummeted by 20000.0% in 2021.
  • TherapeuticsMD's Depreciation and Depletion (Quarter) stood at $59989.0 in 2018, then soared by 193.8% to $176250.0 in 2019, then grew by 13.48% to $200000.0 in 2020, then crashed by 200.0% to -$200000.0 in 2021, then soared by 200.0% to $200000.0 in 2022.
  • Its Depreciation and Depletion was $200000.0 in Q4 2022, compared to $200000.0 in Q3 2022 and $200000.0 in Q2 2022.